Trial Profile
A Randomised, Crossover, Double-blind, Placebo-Controlled study to evaluate the Pharmacodynamics of single oral dose of NDI-010976 (GS-0976) in healthy Obese subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Nov 2017
Price :
$35
*
At a glance
- Drugs Firsocostat (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Pharmacodynamics
- 24 Oct 2017 Results assessing de novo lipogenesis and fatty acid oxidation as potential pharmacodynamic biomarkers of GS-0976 activity (n=10), presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 21 Sep 2017 New trial record
- 01 Aug 2017 Results published in the Hepatology